AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20354490 — intervention group
Group type: COMPARATOR
Intervention: PTA alone
Number of subjects: 60
Study 20354490 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 20354490 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 60
Study 20354490 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus coated stent
Number of subjects: 60
Study 18518674 — intervention group
Group type: EXPERIMENTAL
Intervention: autologous periosteal cells in a fibrin/polyglactin-poly-p-dioxanone fleece
Number of subjects: 24
Study 18518674 — intervention group
Group type: COMPARATOR
Intervention: autologous iliac crest cancellous bone
Number of subjects: 24
Study 16873950 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg coenzyme Q(10) soft oil capsules
Number of subjects: 60
Study 16873950 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg coenzyme Q(10) soft oil capsules
Number of subjects: 60
Study 16873950 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg crystalline Q(10) powder capsules
Number of subjects: 60
Study 16873950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11934231 — intervention group
Group type: EXPERIMENTAL
Intervention: PulmoSphere particles (99mTc‐radiolabeled)
Number of subjects: 9
Study 11934231 — intervention group
Group type: COMPARATOR
Intervention: Evohaler pMDI (micronized particles)
Number of subjects: 9
Study 10075336 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified biscuits (fortified with iron, iodine, and beta-carotene) consumed for 43 weeks over a 12-month period
Number of subjects: 115
Study 10075336 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified biscuits
Number of subjects: 115
Study 10075336 — intervention group
Group type: COMPARATOR
Intervention: Nonfortified biscuits (control group)
Number of subjects: 115
Study 9150971 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute psychological stress test (mirror drawing, watching horror video, arithmetic under intermittent noise)
Number of subjects: 43
Study 1922205 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 120
Study 1922205 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus dietary calcium supplementation
Number of subjects: 120
Study 1922205 — intervention group
Group type: COMPARATOR
Intervention: Exercise plus continuous replacement of estrogen and progesterone
Number of subjects: 120
Study 1922205 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal bone density)
Number of subjects: 120
Study 387704 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 230
Study 387704 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus cephaloridine
Number of subjects: 230
Study 387704 — intervention group
Group type: COMPARATOR
Intervention: Cephaloridine
Number of subjects: 230
Study 31989684 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop system
Number of subjects: 22
Study 31107133 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior tympanomeatal flap elevation
Number of subjects: 26
Study 31107133 — intervention group
Group type: COMPARATOR
Intervention: Posterior tympanomeatal flap elevation
Number of subjects: 26
Study 28002096 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg duloxetine
Number of subjects: 0
Study 28002096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25836698 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimisation group (B) - CT pitch increment and lowering tube current
Number of subjects: 50
Study 25836698 — intervention group
Group type: COMPARATOR
Intervention: Control group (A) - standard CT examination
Number of subjects: 50
Study 23803687 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication partner training (JOINT)
Number of subjects: 44
Study 23803687 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual treatment (TBI SOLO)
Number of subjects: 44
Study 23803687 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 44
Study 17721974 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult sexual abuse (ASA) group
Number of subjects: 69
Study 17721974 — intervention group
Group type: COMPARATOR
Intervention: Non-adult sexual abuse (non-ASA) group
Number of subjects: 69
Study 15041924 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 0
Study 15041924 — intervention group
Group type: EXPERIMENTAL
Intervention: New methods improving specificity and sensitivity of PSA test
Number of subjects: 0
Study 15041924 — intervention group
Group type: EXPERIMENTAL
Intervention: New molecular forms of PSA (PSA isoforms)
Number of subjects: 0
Study 10845900 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood stem cell transplantation
Number of subjects: 824
Study 10845900 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow transplantation
Number of subjects: 824
Study 9354315 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide + Meloxicam (15 mg)
Number of subjects: 19
Study 9354315 — intervention group
Group type: COMPARATOR
Intervention: Frusemide (Control)
Number of subjects: 19
Study 8408734 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (7.5 micrograms/min for 30 minutes followed by 5 micrograms/min for 120 minutes)
Number of subjects: 11
Study 8408734 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 11
Study 8408734 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 11
Study 3006414 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg bolus in 20 ml normal saline)
Number of subjects: 6
Study 3006414 — intervention group
Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 6
Study 3006414 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 6
Study 31010499 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preoperative pain neuroscience education (PNE) session plus therapeutic exercise
Number of subjects: 0
Study 31010499 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative care plus therapeutic exercise
Number of subjects: 0
Study 28029752 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 1 mg
Number of subjects: 301
Study 28029752 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 8 mg
Number of subjects: 301
Study 28029752 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 301
Study 26801163 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium
Number of subjects: 120
Study 26801163 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (control)
Number of subjects: 120
Study 24946562 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Wuzhigan capsules (2 capsules one time, three times a day for 3 days)
Number of subjects: 120
Study 24946562 — intervention group
Group type: COMPARATOR
Intervention: Compound Wuzhigan tablets (4 tablets one time, three times a day for 3 days)
Number of subjects: 120
Study 22001942 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg for 8 weeks
Number of subjects: 112
Study 22001942 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg for 4 weeks
Number of subjects: 112
Study 19223667 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated reading training
Number of subjects: 59
Study 19223667 — intervention group
Group type: COMPARATOR
Intervention: Unaccelerated reading training
Number of subjects: 59
Study 17258926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multitherapy (IMT)
Number of subjects: 72
Study 17258926 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 15100501 — intervention group
Group type: EXPERIMENTAL
Intervention: F-FDG PET
Number of subjects: 26
Study 15100501 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 26
Study 15100501 — intervention group
Group type: EXPERIMENTAL
Intervention: SRS
Number of subjects: 26
Study 12139561 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal cultures from healthy infants and children
Number of subjects: 1404
Study 12139561 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at day-care centers (DCC)
Number of subjects: 1404
Study 12139561 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at elementary schools (ES)
Number of subjects: 1404
Study 12139561 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib isolates susceptibility testing
Number of subjects: 1404
Study 12139561 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of predictors
Number of subjects: 1404
Study 9814473 — intervention group
Group type: EXPERIMENTAL
Intervention: Human CG (10 U/mL)
Number of subjects: 0
Study 9814473 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-1 (10 ng/mL)
Number of subjects: 0
Study 9814473 — intervention group
Group type: COMPARATOR
Intervention: Interleukin (IL)-4 (10 ng/mL)
Number of subjects: 0
Study 9814473 — intervention group
Group type: COMPARATOR
Intervention: Interleukin (IL)-10 (10 ng/mL)
Number of subjects: 0
Study 7649498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate
Number of subjects: 84
Study 7649498 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 84
Study 7649498 — intervention group
Group type: COMPARATOR
Intervention: Cyclandelate and Propranolol
Number of subjects: 84
Study 2468927 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (1, 1, 2, and 4 mg)
Number of subjects: 24
Study 2468927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicloprolol (0.025, 0.025, 0.05, and 0.1 mg/kg)
Number of subjects: 24
Study 7095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (2 mg/kg body weight, supplemented if necessary by 1 mg/kg) + Flunitrazepam (2 mg)
Number of subjects: 140
Study 7095 — intervention group
Group type: COMPARATOR
Intervention: Ketamine (2 mg/kg body weight, supplemented if necessary by 1 mg/kg)
Number of subjects: 140
Study 31456003 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy (RT) with single doses of 0.5Gy (total dose 3.0-5.0Gy)
Number of subjects: 598
Study 31456003 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy (RT)
Number of subjects: 598
Study 28711972 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c levels
Number of subjects: 1441
Study 25868059 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (220 mg zinc sulfate containing 50 mg zinc)
Number of subjects: 52
Study 23892423 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol for management of interval appendectomy
Number of subjects: 45
Study 22509642 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (5 doses of 2.5 ml each, one dose per week)
Number of subjects: 40
Study 22509642 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone (single 2 ml dose)
Number of subjects: 40
Study 19874153 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose naltrexone (100 mg/d)
Number of subjects: 87
Study 19874153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) without Contingency Management (CM)
Number of subjects: 87
Study 19874153 — intervention group
Group type: COMPARATOR
Intervention: Contingency Management (CM) added to CBT
Number of subjects: 87
Study 19874153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 16923926 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine treatment
Number of subjects: 196
Study 16923926 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 196
Study 15365066 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2) every 3 weeks for four cycles
Number of subjects: 1458
Study 11176936 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary myelin basic protein-like material (MBPLM)
Number of subjects: 662
Study 9135893 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 Gy in two fractions (1 week apart)
Number of subjects: 216
Study 9135893 — intervention group
Group type: COMPARATOR
Intervention: 22.5 Gy in five daily fractions
Number of subjects: 216
Study 9135893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 216
Study 7962328 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-deficient group (panhypopituitary patients)
Number of subjects: 20
Study 7962328 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 20
Study 2958947 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous procaine penicillin G (4.8 X 10(6) units im plus 1.0 g of oral probenicid)
Number of subjects: 140
Study 2958947 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ampicillin (3.5 g plus 1.0 g of oral probenicid)
Number of subjects: 140
Study 2958947 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectinomycin (2.0 g im)
Number of subjects: 140
Study 2958947 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rosoxacin (300 mg)
Number of subjects: 140
Study 28479405 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified WM training (25 sessions)
Number of subjects: 91
Study 28479405 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified WM training
Number of subjects: 91
Study 28479405 — intervention group
Group type: COMPARATOR
Intervention: Sham training (control)
Number of subjects: 91
Study 27260149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2 μg/kg (Group I)
Number of subjects: 105
Study 27260149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal clonidine 3 μg/kg (Group II)
Number of subjects: 105
Study 27260149 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline 0.5 ml (Group III)
Number of subjects: 105
Study 27260149 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dexmedetomidine and clonidine
Number of subjects: 105
Study 24630881 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (smokers)
Number of subjects: 13819
Study 21614497 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal massage with Vaseline
Number of subjects: 90
Study 21614497 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 19912160 — intervention group
Group type: COMPARATOR
Intervention: Control epidural (bupivacaine)
Number of subjects: 1054
Study 19912160 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Spinal Epidural
Number of subjects: 1054
Study 19912160 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Dose Infusion
Number of subjects: 1054
Study 19912160 — intervention group
Group type: COMPARATOR
Intervention: Non-epidural
Number of subjects: 1054
Study 19912160 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age groups
Number of subjects: 1054
Study 19912160 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-white ethnicity
Number of subjects: 1054
Study 18421802 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid tryptophan depletion test (RTD)
Number of subjects: 22
Study 18421802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16409700 — intervention group
Group type: EXPERIMENTAL
Intervention: Support counselling by the embryologist
Number of subjects: 60
Study 16409700 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatment, no counselling)
Number of subjects: 60
Study 12559938 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab + primary PTCA
Number of subjects: 31
Study 12559938 — intervention group
Group type: COMPARATOR
Intervention: primary PTCA alone
Number of subjects: 31
Study 11151875 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral erythromycin
Number of subjects: 37
Study 11151875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 8606267 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU of urokinase (group A)
Number of subjects: 98
Study 8606267 — intervention group
Group type: EXPERIMENTAL
Intervention: 500,000 IU of urokinase (group B)
Number of subjects: 98
Study 1334539 — intervention group
Group type: COMPARATOR
Intervention: cisplatin (80 mg/m2, day 1)/etoposide (100 mg/m2, days 1, 3, 5) (PE)
Number of subjects: 92
Study 1334539 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin (80 mg/m2, day 1)/etoposide (100 mg/m2, days 1, 3, 5)/ifosfamide (2 g/m2, days 1, 2, 3) (PEI)
Number of subjects: 92
Study 6466532 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 10 micrograms kg‐1
Number of subjects: 0
Study 6466532 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 20 micrograms kg‐1
Number of subjects: 0
Study 6466532 — intervention group
Group type: COMPARATOR
Intervention: Control group (lower dose range of glycopyrrolate and atropine)
Number of subjects: 0
Study 31382232 — intervention group
Group type: EXPERIMENTAL
Intervention: TUG test with picture condition under qualitative verbal instructions
Number of subjects: 210
Study 31382232 — intervention group
Group type: EXPERIMENTAL
Intervention: TUG test with picture condition under nonqualitative verbal instructions
Number of subjects: 210
Study 31382232 — intervention group
Group type: EXPERIMENTAL
Intervention: TUG test with qualitative verbal instructions
Number of subjects: 210
Study 31382232 — intervention group
Group type: COMPARATOR
Intervention: TUG test with nonqualitative verbal instructions
Number of subjects: 210
Study 28122609 — intervention group
Group type: COMPARATOR
Intervention: Standard telePRO
Number of subjects: 0
Study 28122609 — intervention group
Group type: EXPERIMENTAL
Intervention: Open access telePRO
Number of subjects: 0
Study 25689725 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotherapeutic intervention (wake group)
Number of subjects: 75
Study 25689725 — intervention group
Group type: COMPARATOR
Intervention: Exercise group
Number of subjects: 75
Study 23547079 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y-ibritumomab
Number of subjects: 409
Study 23547079 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 409
Study 21696081 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% isobaric racemic bupivacaine 3 mL
Number of subjects: 70
Study 21696081 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% isobaric levobupivacaine 3 mL
Number of subjects: 70
Study 18713312 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid infusion (HCl 0.15 mol L(‐1))
Number of subjects: 18
Study 18713312 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 18
Study 18713312 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid infusion aspirated 3 cm distally
Number of subjects: 18
Study 16710092 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.25 microg.kg(‐1) continuous infusion)
Number of subjects: 62
Study 16710092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 16710092 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 62
Study 12456442 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (0.6 mg) combined with epidural neostigmine (60 micro g)
Number of subjects: 60
Study 12456442 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 60
Study 12456442 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural neostigmine (60 micro g)
Number of subjects: 60
Study 12456442 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (0.6 mg)
Number of subjects: 60
Study 10525786 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scanning at 125 or 150 mAs
Number of subjects: 100
Study 10525786 — intervention group
Group type: COMPARATOR
Intervention: CT scanning at 200 or 250 mAs
Number of subjects: 100
Study 7793646 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyck parameter set
Number of subjects: 30
Study 7793646 — intervention group
Group type: COMPARATOR
Intervention: Marsh parameter set
Number of subjects: 30
Study 7793646 — intervention group
Group type: COMPARATOR
Intervention: Tackley parameter set
Number of subjects: 30
Study 2024911 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril/Hydrochlorothiazide (E/HCTZ: 20/12.5-40/25 mg)
Number of subjects: 146
Study 2024911 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (E: 20-40 mg)
Number of subjects: 146
Study 2024911 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ: 12.5-25 mg)
Number of subjects: 146
Study 7282909 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive antibiotic treatment with clindamycin and gentamycin
Number of subjects: 72
Study 7282909 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic therapy
Number of subjects: 72
Study 6421007 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN (Isosorbide dinitrate) - mean dose 15.5 micrograms kg‐1 min‐1
Number of subjects: 17
Study 6421007 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG (Nitroglycerin) - mean dose 5.5 micrograms kg‐1 min‐1
Number of subjects: 17
Study 29924642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg every 8 hours
Number of subjects: 20
Study 29924642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29924642 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen and Placebo
Number of subjects: 20
Study 26414108 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAPT) - aspirin plus clopidogrel plus cilostazol (100 mg loading, followed with 50 mg twice per day) for 3-6 months
Number of subjects: 127
Study 26414108 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) - aspirin plus clopidogrel
Number of subjects: 127
Study 26414108 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPT
Number of subjects: 127
Study 26414108 — intervention group
Group type: COMPARATOR
Intervention: DAPT
Number of subjects: 127
Study 25536256 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation
Number of subjects: 44567
Study 25536256 — intervention group
Group type: COMPARATOR
Intervention: Iron-folic acid supplementation
Number of subjects: 44567
Study 22158330 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol treatment
Number of subjects: 648
Study 20299481 — intervention group
Group type: EXPERIMENTAL
Intervention: Online diabetes self-management program
Number of subjects: 761
Study 20299481 — intervention group
Group type: EXPERIMENTAL
Intervention: Online diabetes self-management program with initial A1C >7%
Number of subjects: 761